![PDF) ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease PDF) ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease](https://i1.rgstatic.net/publication/350133906_ECCO_Guidelines_on_the_Prevention_Diagnosis_and_Management_of_Infections_in_Inflammatory_Bowel_Disease/links/60530eeb92851cd8ce4bd73b/largepreview.png)
PDF) ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
![Mistakes in opportunistic infections and vaccinations in IBD and how to avoid them | UEG - United European Gastroenterology Mistakes in opportunistic infections and vaccinations in IBD and how to avoid them | UEG - United European Gastroenterology](https://ueg.eu/images/2272/743394beff4b1282ba735e5e3723ed74_975_LARGE.png)
Mistakes in opportunistic infections and vaccinations in IBD and how to avoid them | UEG - United European Gastroenterology
Apostolis Papaefthymiou on LinkedIn: A cutting edge review for IBD related NAFLD (IBDAFLD). This is a real…
![Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics? | American Journal of Physiology-Gastrointestinal and Liver Physiology Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics? | American Journal of Physiology-Gastrointestinal and Liver Physiology](https://journals.physiology.org/cms/10.1152/ajpgi.00002.2022/asset/images/medium/gi-00002-2022r01.png)
Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics? | American Journal of Physiology-Gastrointestinal and Liver Physiology
![Metabolites | Free Full-Text | What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature Metabolites | Free Full-Text | What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature](https://www.mdpi.com/metabolites/metabolites-13-00378/article_deploy/html/images/metabolites-13-00378-g001.png)
Metabolites | Free Full-Text | What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature
![Call for nominations for participants in the 21st ECCO IBD Intensive Course for Trainees - The British Society of Gastroenterology Call for nominations for participants in the 21st ECCO IBD Intensive Course for Trainees - The British Society of Gastroenterology](https://www.bsg.org.uk/wp-content/uploads/2020/10/ECCO.png)
Call for nominations for participants in the 21st ECCO IBD Intensive Course for Trainees - The British Society of Gastroenterology
![COVID-19 and IBD: Guidance from IOIBD and ECCO on management of patients | International Organization For the Study of Inflammatory Bowel Disease COVID-19 and IBD: Guidance from IOIBD and ECCO on management of patients | International Organization For the Study of Inflammatory Bowel Disease](https://ioibd.org/wp-content/uploads/2020/11/front_matter-JCC-Journal-pdf.jpg)
COVID-19 and IBD: Guidance from IOIBD and ECCO on management of patients | International Organization For the Study of Inflammatory Bowel Disease
EMJ - We are excited to share the latest supplement to our EMJ Gastroenterology eJournal. Read this issue for valuable insights in the form of scientific highlights and features describing the recent
![PDF) N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis PDF) N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis](https://i1.rgstatic.net/publication/247156190_N-ECCO_Consensus_statements_on_the_European_nursing_roles_in_caring_for_patients_with_Crohn's_disease_or_ulcerative_colitis/links/5d1b6af0a6fdcc2462b92ebb/largepreview.png)
PDF) N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis
![Peter Bossuyt, ECCO-IBD 2022: Risankizumab in Crohn's Disease - Post Hoc Analysis of ADVANCE, MOTIVATE, and FORTIFY - touchIMMUNOLOGY Peter Bossuyt, ECCO-IBD 2022: Risankizumab in Crohn's Disease - Post Hoc Analysis of ADVANCE, MOTIVATE, and FORTIFY - touchIMMUNOLOGY](https://www.touchimmunology.com/wp-content/uploads/sites/18/2022/03/TMM-IMMUNOLOGY-Peter-Bossuyt-thumbnail.jpg)